Mammary Cell News Volume 10.47 | Nov 29 2018

TOP STORY

High-Resolution Clonal Mapping of Multi-Organ Metastasis in Triple Negative Breast Cancer

Clonal dynamics during metastasis were studied in vivo using two patient-derived xenograft models established from the treatment-naive primary breast tumors of triple negative breast cancer patients diagnosed with synchronous metastasis. [Nat Commun] Full Article

(Ranked by impact factor of the journal)

ERRα Promotes Breast Cancer Cell Dissemination to Bone by Increasing RANK Expression in Primary Breast Tumors

The authors established that estrogen-related-receptor alpha (ERRα) promoted spontaneous metastatic dissemination of breast cancer cells from primary mammary tumors to the skeleton. [Oncogene] Abstract

Conditional Knockout of SHP2 in ErbB2 Transgenic Mice or Inhibition in HER2-Amplified Breast Cancer Cell Lines Blocks Oncogene Expression and Tumorigenesis

Scientists showed that inhibition of Src homology phosphotyrosyl phosphatase 2 (SHP2) encoded by the PTPN11 gene in the human epidermal growth factor receptor 2 (HER2)-amplified breast cancer cells induced a normal-like cellular phenotype and suppressed tumorigenesis and metastasis by blocking HER2 overexpression. [Oncogene] Abstract

The Pro-Metastasis Effect of circANKS1B in Breast Cancer

Gain- and loss-of-function experiments in cell lines and mouse xenograft models were performed to support clinical findings and elucidate the function and underlying mechanisms of circANKS1B in breast cancer. [Mol Cancer] Full Article

Dasatinib Sensitises Triple Negative Breast Cancer Cells to Chemotherapy by Targeting Breast Cancer Stem Cells

Scientists generated paclitaxel-resistant triple negative breast cancer cells which displayed higher sphere forming potential and percentage of breast cancer stem cell subpopulations compared to the parental cells. [Br J Cancer] Abstract

Zinc Finger Protein 32 Promotes Breast Cancer Stem Cell-Like Properties through Directly Promoting GPER Transcription

Investigators examined the relationship between zinc finger protein 32 and GPER, a membrane-associated estrogen receptor, and they addressed their roles in stemness regulation in human breast cancer cell lines. [Cell Death Dis] Full Article

HER4 Expression in Estrogen Receptor-Positive Breast Cancer Is Associated with Decreased Sensitivity to Tamoxifen Treatment and Reduced Overall Survival of Postmenopausal Women

The authors found a significantly improved survival in tamoxifen-treated postmenopausal breast cancer patients in the absence of HER4 compared with those with pronounced HER4 expression. The sensitivity to tamoxifen treatment of estrogen and HER4 receptor-positive ZR-75-1 breast cancer cells was significantly enhanced by HER4 knockdown. [Breast Cancer Res] Full Article

CCR2 Chemokine Receptors Enhance Growth and Cell Cycle Progression of Breast Cancer Cells through SRC and PKC Activation

Researchers demonstrated important biological roles for CCL2/CCR2 signaling in breast cancer cells. Using the MCF10CA1d xenograft model of basal-like breast cancer, primary tumor growth was significantly increased with co-transplantation of patient derived fibroblasts expressing high levels of CCL2, and was inhibited with CRISP/R gene ablation of stromal CCL2. [Mol Cancer Res] Abstract

Collagen Density Modulates Triple-Negative Breast Cancer Cell Metabolism through Adhesion-Mediated Contractility

Investigators found that only triple-negative breast cancer cells, MDA-MB231 and MDA-MB468 cells, had an increased population of bound NADH, indicating an oxidative phosphorylation signature, as collagen density decreased. [Sci Rep] Full Article

Upregulation of Ets1 Expression by NFATc2 and NFKB1/RELA Promotes Breast Cancer Cell Invasiveness

Compared with less metastatic breast cancer cells, metastatic breast cancer cells showed open chromatin configurations in the core-regulatory element, which facilitated direct binding of NFATc2 and/or NFKB1/RELA complex to trans-activate ETS proto-oncogene 1 (Ets1) transcription. [Oncogenesis] Full Article

C11, a Novel Fibroblast Growth Factor Receptor 1 (FGFR1) Inhibitor, Suppresses Breast Cancer Metastasis and Angiogenesis

C11 inhibited breast cancer MDA-MB-231 cell migration and invasion via suppression of FGFR1 phosphorylation and its downstream signaling pathway. [Acta Pharmacol Sin] Abstract

Cyclin E1 and Rb Modulation as Common Events at Time of Resistance to Palbociclib in Hormone Receptor-Positive Breast Cancer

Scientists profiled a large panel of hormone receptor-positive breast cancer cell lines with conditioned resistance to the CDK4/6 inhibitor palbociclib, and analyzed cell cycle-related markers by gene expression profiles and western blot. [npj Breast Cancer] Full Article

Subscribe to one of our other 19 science newsletters such as Prostate Cell News & ESC & iPSC News.

Cancer-Associated Fibroblasts as Key Regulators of the Breast Cancer Tumor Microenvironment

The authors discuss the impact of cancer-associated fibroblasts (CAFs) on breast cancer biology and highlights their heterogeneity, origin and their role in tumor progression, ECM remodeling, therapy resistance, metastasis, and the challenges ahead of targeting CAFs to improve therapy response. [Cancer Metastasis Rev] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

Zymeworks and BeiGene Announce License and Collaboration Agreement for Zymeworks’ HER2-Targeted Therapeutic Candidates, ZW25 and ZW49, in Asia-Pacific and Research and License Agreement for Zymeworks’ Azymetric™ and EFECT™ Platforms Globally

Zymeworks Inc. and BeiGene, Ltd. announced that the two companies have entered into a strategic collaboration for the clinical development and commercialization of Zymeworks’ investigational ZW25 and ZW49 HER2-targeted bispecific antibodies. [Zymeworks Inc.] Press Release

CytoDyn Announces Initiation of Metastatic Triple Negative Breast Cancer Trial and Reiterates Phase III Goal in Cancer

CytoDyn Inc. announced that on November 23, 2018, it received FDA approval of its IND submission and is allowed to initiate a Phase Ib/II clinical trial for metastatic triple-negative breast cancer patients. [CytoDyn Inc.] Press Release

SELLAS Life Sciences Announces Completion of Enrollment in Phase II Randomized Controlled Clinical Study of Nelipepimut-S Plus Trastuzumab in High-Risk, High-Expression HER2 Breast Cancer Patients

SELLAS Life Sciences Group, Inc. announced the completion of enrollment for a Phase II independent investigator-sponsored clinical trial of the combination of trastuzumab +/- nelipepimut-S targeting high-risk, high-expression HER2-positive breast cancer patients. [SELLAS Life Sciences Group, Inc.] Press Release

Generex Biotechnology Signs Clinical Trial Agreement with the NSABP Foundation, Inc. for Phase II Clinical Trial of AE37 in Combination with Pembrolizumab (Keytruda^®) for Treatment of Triple-Negative Breast Cancer

Generex Biotechnology Corporation has signed a clinical trial agreement with the NSABP Foundation, Inc. (NSABP), to manage a Phase II clinical trial of pembrolizumab in combination with the AE37 peptide vaccine in patients with metastatic triple negative breast cancer. [Generex Biotechnology Corporation] Press Release

Does Science Have a Bullying Problem?

A spate of bullying allegations have rocked several high-profile science institutions. Here’s how researchers, universities, funders and others are dealing with the issue. [Nature News] Editorial

China Halts Genome Editing Research That Led to Claimed Birth of CRISPR Babies

The Chinese government said it had halted research that allegedly led to the births of the world’s first gene-edited babies, as the organizers of an international summit on human genome editing made clear that such research should not have been done and that, for now, similar attempts should not be made. [STAT News] Editorial

Biomedical Research Is Becoming More Open about Its Funding and Data

Biomedical research is shifting to become more open and transparent by providing increasing amounts of information about funding, conflicts of interest and data sharing in their publications, according to a survey of recent papers. [Nature News] Editorial

European Funders Detail Their Open-Access Plan

Plan S, the contentious plan that a group of European science funders hopes will end scholarly journals’ paywalls, has fleshed out its rules—and softened its tone a bit. In seven pages of implementation guidance released, the funders explain how their grantees can abide by Plan S rules come 2020, when it goes into effect. But some critics say the document—which is up for public discussion for the next two months—remains too restrictive. [ScienceInsider] Editorial

NEW 31^st International Association for Breast Cancer Research Conference
April 15-18, 2019
Egmond aan Zee, Netherlands

Visit our events page to see a complete list of events in the community.

NEW Associate Research Scientist/Postdoctoral Research Scientist – Molecular Genetics (Columbia University Medical Center)

NEW Faculty Position – Cancer Cell Signaling (The University of New Mexico Comprehensive Cancer Center)

Postdoctoral Research Associate – Cell Based Assays (University of Oxford)

Postdoctoral Associate – Molecular and Cell Biology (Baylor College of Medicine)

Faculty Position – Cancer Pathobiology (University of Alabama at Birmingham)

Research Fellow – Immunology (King’s College London)

Postdoctoral Position – Novel Cancer Gene and Therapy (University of Notre Dame)

Epigenetic Reprogramming of Enhancers During Breast Cancer Progression (Università degli Studi di Trento)

Postdoctoral Fellowship – Epigenetics and RNA Biology (Umeå University)

Postdoctoral Fellow – Stem Cells and Cancer (Albert Einstein College of Medicine)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.